In accordance with opposition procedures, Nutri Pharma will defend its granted European patent before the Opposition Division (OD) of the EPO.
"Given the recognised commercial importance of Nutri Pharma's patented technology, the filing of an opposition was not unexpected," said Graham Waters, Chief Executive of Nutri Pharma.
Nutri Pharma's IP portfolio comprises a total of 12 patent-families and applications, and with a total of around 750 claims. The filing of an opposition concerns 1 of these patent-families.
